LOGIN  |  REGISTER
Assertio
Amneal Pharmaceuticals

Natera to Participate in Upcoming Investor Conferences

February 24, 2023 | Last Trade: US$105.29 9.74 10.19

AUSTIN, Texas / Feb 24, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its management team will present at the following investor conferences:

  • Raymond James 44th Annual Institutional Investors Conference on Tuesday, March 7 at 2:50 p.m. ET in Orlando, FL
  • Cowen 43rd Annual Health Care Conference on Wednesday, March 8 at 11:10 a.m. ET in Boston, MA

A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of each event will be available shortly following the conferences.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Surmodics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB